Products in Development
Based on our patented submicron particle production technology platform, these investigational drugs are in preclinical or clinical development for treatment of cancer and other serious illnesses.
(Sterile Submicron Particle Paclitaxel for Suspension)

Ovarian Cancer (intraperitoneal)
Prostate Cancer (intratumoral)
Pancreatic Cancer (intratumoral)
Pancreatic Mucinous Cysts (intracystic)

(Submicron Particle Paclitaxel for Nebulized Inhalation)

Non-Small Cell Lung Cancer (inhalation)

(Sterile Submicron Particle Docetaxel for Suspension)

Bladder Cancer (local)
Renal Cancer (intratumoral)
Breast Cancer (intratumoral)

Topical Submicron Particle Paclitaxel

 (Submicron Particle Paclitaxel Suspended in Anhydrous Base)

Cutaneous Metastases

Topical Submicron Particle Paclitaxel

 (Submicron Particle Paclitaxel Suspended in Anhydrous Base)

Actinic Keratosis
Cervical Intraepithelial Neoplasia
By NanOlogy affiliate, Soria


  • Formed by a patented, controlled submicron particle production process using sonic energy and supercritical fluid carbon dioxide to reduce unprocessed paclitaxel and docetaxel API crystals by up to 400 times into submicron particles with exponentially increased surface area and unique geometry
  • Stable, uncoated “naked” submicron paclitaxel and docetaxel particles with narrow distribution around mean particle size
  • Submicron particles so unique they have been granted a composition of matter patent valid in the United States until 2036
  • Unlike conventional micronization via milling, no energy is added to the paclitaxel and docetaxel particles allowing them to remain free-flowing, stable, suitable for pharmaceutical manufacturing without solvents, coating agents, or carriers
  • Exponential increase in surface area allows for suspendability of the paclitaxel and docetaxel submicron particles in simple vehicles and local therapeutic release of active drug molecules over weeks


  • Ability to deliver large amounts of NanoPac or NanoDoce directly to the site of disease where the submicron particles remain, continuously releasing drug over time
  • Intraperitoneal delivery of NanoPac is retained in the peritoneum for more than four weeks
  • Topically applied NanoPac penetrates into the dermis
  • Preclinical and clinical evidence of activity and immune stimulation
  • Gradual clearance of NanoPac and NanoDoce at subtoxic levels from local site of administration
  • Particles of pure drug without coating or carrier agents eliminates need for toxic solvents like Cremophor
  • Extensive global IP portfolio of issued and pending patents covering submicron particle characteristics, compositions, specifications, uses, formulations, process, therapeutic combinations and other important aspects of NanoPac and NanoDoce